Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
251 patients with unresectable HCC who received Atez and Bev in the IMbrave150 trial.
I · Intervention 중재 / 시술
Atez and Bev in the IMbrave150 trial
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS AND RELEVANCE] In this exploratory analysis, temporary interruptions of Atez or Bev were not associated with worse survival outcomes in patients with unresectable HCC. Prospective studies are needed to validate these findings.
[IMPORTANCE] Atezolizumab (Atez) combined with bevacizumab (Bev) is the recommended first-line treatment for unresectable hepatocellular carcinoma (HCC).
- 95% CI 0.90-2.73
- HR 1.57
APA
Xu XQ, Li WM, et al. (2025). Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.. The oncologist, 30(9). https://doi.org/10.1093/oncolo/oyaf269
MLA
Xu XQ, et al.. "Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.." The oncologist, vol. 30, no. 9, 2025.
PMID
40891895
Abstract
[IMPORTANCE] Atezolizumab (Atez) combined with bevacizumab (Bev) is the recommended first-line treatment for unresectable hepatocellular carcinoma (HCC). However, the clinical impact of temporary interruptions of Atez and Bev on treatment outcomes remains unclear.
[OBJECTIVE] To evaluate the association between temporary interruptions of Atez or Bev and survival outcomes among patients with unresectable HCC.
[DESIGN] Exploratory post hoc analysis of patient-level data from the phase 3 IMbrave150 (NCT03434379) trial.
[SETTING] Global, multicenter, randomized phase 3 trial designed to evaluate the therapeutic benefit of Atez plus Bev compared with sorafenib in patients with unresectable HCC.
[PARTICIPANTS] A total of 251 patients with unresectable HCC who received Atez and Bev in the IMbrave150 trial.
[EXPOSURES] Temporary interruptions of Atez or Bev during treatment.
[MAIN OUTCOMES AND MEASURES] Overall survival (OS) and progression-free survival (PFS).
[RESULTS] Among 251 patients treated with Atez/Bev, 79 (31.5%) experienced Atez interruptions and 86 (34.3%) had Bev interruptions. Interruptions were not significantly associated with OS (HR = 1.57, 95% CI: 0.90-2.73 for Atez, HR = 0.50, 95% CI: 0.16-1.53 for Bev). However, both were significantly associated with improved PFS (HR = 0.56, 95% CI: 0.34-0.92 for Atez and HR = 0.61, 95% CI: 0.39-0.94 for Bev). Subgroup analyses showed that positive association of PFS and interruptions was primarily observed in patients with events or treatment duration <12 months. Early (within 6 months) and late interruptions (after 6 months) showed trends toward longer PFS but were not statistically significant (HR = 0.56, 95% CI: 0.27-1.15 and HR = 0.57, 95% CI: 0.29-1.09 for Atez, HR = 0.61, 95% CI: 0.37-1.02, and HR = 0.60, 95% CI: 0.29-1.27 for Bev).
[CONCLUSIONS AND RELEVANCE] In this exploratory analysis, temporary interruptions of Atez or Bev were not associated with worse survival outcomes in patients with unresectable HCC. Prospective studies are needed to validate these findings.
[OBJECTIVE] To evaluate the association between temporary interruptions of Atez or Bev and survival outcomes among patients with unresectable HCC.
[DESIGN] Exploratory post hoc analysis of patient-level data from the phase 3 IMbrave150 (NCT03434379) trial.
[SETTING] Global, multicenter, randomized phase 3 trial designed to evaluate the therapeutic benefit of Atez plus Bev compared with sorafenib in patients with unresectable HCC.
[PARTICIPANTS] A total of 251 patients with unresectable HCC who received Atez and Bev in the IMbrave150 trial.
[EXPOSURES] Temporary interruptions of Atez or Bev during treatment.
[MAIN OUTCOMES AND MEASURES] Overall survival (OS) and progression-free survival (PFS).
[RESULTS] Among 251 patients treated with Atez/Bev, 79 (31.5%) experienced Atez interruptions and 86 (34.3%) had Bev interruptions. Interruptions were not significantly associated with OS (HR = 1.57, 95% CI: 0.90-2.73 for Atez, HR = 0.50, 95% CI: 0.16-1.53 for Bev). However, both were significantly associated with improved PFS (HR = 0.56, 95% CI: 0.34-0.92 for Atez and HR = 0.61, 95% CI: 0.39-0.94 for Bev). Subgroup analyses showed that positive association of PFS and interruptions was primarily observed in patients with events or treatment duration <12 months. Early (within 6 months) and late interruptions (after 6 months) showed trends toward longer PFS but were not statistically significant (HR = 0.56, 95% CI: 0.27-1.15 and HR = 0.57, 95% CI: 0.29-1.09 for Atez, HR = 0.61, 95% CI: 0.37-1.02, and HR = 0.60, 95% CI: 0.29-1.27 for Bev).
[CONCLUSIONS AND RELEVANCE] In this exploratory analysis, temporary interruptions of Atez or Bev were not associated with worse survival outcomes in patients with unresectable HCC. Prospective studies are needed to validate these findings.